Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today
Key Stats
- $136.93BMarket Cap
- -Volume
- HealthSector
- $552.0652W High
- $376.6252W Low
- -Typical Hold Time
- $131.06BEnterprise Value
- -Div Yield
- -Trading Activity
Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $376.62 and a high of $552.06, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
New York surpasses San Francisco in tech jobs for first time, driven by AI growth.
A CBRE report reveals that New York's office market now hosts more tech workers than San Francisco's for the first time in 13 years, largely due to the rise of AI-related roles. New York has 394,300 tech jobs compared to San Francisco's 375,730, with...
BYD's overseas sales growth offsets China's domestic slowdown, stabilizing overall vehicle sales.
BYD is seeing a stabilization in its business as declines in domestic Chinese sales narrow and total vehicle sales grew in June and July. The company's overseas sales, particularly in Europe and Brazil, have grown enough to significantly impact its o...
Canada backs Focus Graphite's Lac Knife project with funding and infrastructure plans to boost clean energy minerals.
Focus Graphite's Lac Knife Graphite Project in Canada has been recognized and supported by the Canadian government as part of a clean-energy and critical-minerals infrastructure initiative. The project received C$1.38 million in non-repayable federal...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.